MiR-296-5p Suppresses EMT of Hepatocellular Carcinoma Via Attenuating NRG1/ERBB2/ERBB3 Signaling

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2018 Nov 30

PMID 30486894

Citations 53

Authors

Dong-Min Shi

Li-Xin Li

Xin-Yu Bian

Xue-Jiang Shi

Li-Li Lu

Hong-Xin Zhou

Ting-Jia Pan

Jian Zhou

Jia Fan

Wei-Zhong Wu

Affiliations

Soon will be listed here.

Abstract

Background: Accumulation of evidence indicates that miRNAs have crucial roles in the regulation of EMT-associated properties, such as proliferation, migration and invasion. However, the underlying molecular mechanisms are not entirely illustrated. Here, we investigated the role of miR-296-5p in hepatocellular carcinoma (HCC) progression.

Methods: In vitro cell morphology, proliferation, migration and invasion were compared between HCC cell lines with up- or down-regulation of miR-296-5p. Immunofluorescence and Western blot immunofluorescence assays were used to detect the expression of EMT markers. Bioinformatics programs, luciferase reporter assay and rescue experiments were used to validate the downstream targets of miR-296-5p. Xenograft nude mouse models were established to observe tumor growth and metastasis. Immunohistochemical assays were conducted to study the relationships between miR-296-5p expression and Neuregulin-1 (NRG1)/EMT markers in human HCC samples and mice.

Results: miR-296-5p was prominently downregulated in HCC tissues relative to adjacent normal liver tissues and associated with favorable prognosis. Overexpression of miR-296-5p inhibited EMT along with migration and invasion of HCC cells via suppressing NRG1/ERBB2/ERBB3/RAS/MAPK/Fra-2 signaling in vitro. More importantly, miR-296-5p disrupted intrahepatic and pulmonary metastasis in vivo. NRG1, as a direct target of miR-296-5p, mediates downstream biological responses. In HCC tissues from patients and mice, the levels of miR-296-5p and NRG1 also showed an inverse relationship.

Conclusions: miR-296-5p inhibited EMT-related metastasis of HCC through NRG1/ERBB2/ERBB3/RAS/MAPK/Fra-2 signaling.

Citing Articles

MicroRNAs in Hepatocellular Carcinoma Pathogenesis: Insights into Mechanisms and Therapeutic Opportunities.

Mahboobnia K, Beveridge D, Yeoh G, Kabir T, Leedman P Int J Mol Sci. 2024; 25(17).

PMID: 39273339 PMC: 11395074. DOI: 10.3390/ijms25179393.

Talin1 promotes HCC progression by regulating NRG1/PI3K/AKT pathway.

Liu J, Lu Y, Zheng B, Huang D, Song J, Wang B Discov Oncol. 2024; 15(1):360.

PMID: 39162903 PMC: 11335986. DOI: 10.1007/s12672-024-01243-2.

Genetic Alchemy unveiled: MicroRNA-mediated gene therapy as the Artisan craft in the battlefront against hepatocellular carcinoma-a comprehensive chronicle of strategies and innovations.

Murshed A, Alnoud M, Ahmad S, Ullah Khan S, Alissa M, Alsuwat M Front Genet. 2024; 15:1356972.

PMID: 38915826 PMC: 11194743. DOI: 10.3389/fgene.2024.1356972.

β-Sitosterol alleviates the malignant phenotype of hepatocellular carcinoma cells via inhibiting GSK3B expression.

Wang R, Tang D, Ou L, Jiang J, Wu Y, Tian X Hum Cell. 2024; 37(4):1156-1169.

PMID: 38814517 PMC: 11194219. DOI: 10.1007/s13577-024-01081-y.

Hsa-circ-0006091 modulates the proliferation of hepatocellular carcinoma via the miR-622/CCNB1 axis.

Zhao X, He L Turk J Med Sci. 2024; 53(5):1367-1378.

PMID: 38813026 PMC: 10763780. DOI: 10.55730/1300-0144.5703.

References

Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

Li Y, Tang Y, Ye L, Liu B, Liu K, Chen J . Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol. 2003; 129(1):43-51. DOI: 10.1007/s00432-002-0396-4. View

Eisen M, Spellman P, Brown P, Botstein D . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95(25):14863-8. PMC: 24541. DOI: 10.1073/pnas.95.25.14863. View

Li T, Lu Y, Zhao X, Guo H, Liu C, Li H . MicroRNA-296-5p increases proliferation in gastric cancer through repression of Caudal-related homeobox 1. Oncogene. 2013; 33(6):783-93. DOI: 10.1038/onc.2012.637. View

Langmead B, Salzberg S . Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012; 9(4):357-9. PMC: 3322381. DOI: 10.1038/nmeth.1923. View

Zhu X, Zhang J, Zhuang P, Zhu H, Zhang W, Xiong Y . High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008; 26(16):2707-16. DOI: 10.1200/JCO.2007.15.6521. View

Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg S . TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013; 14(4):R36. PMC: 4053844. DOI: 10.1186/gb-2013-14-4-r36. View

Lee H, Shin C, Kim H, Choi K, Kim H . MicroRNA-296-5p Promotes Invasiveness through Downregulation of Nerve Growth Factor Receptor and Caspase-8. Mol Cells. 2016; 40(4):254-261. PMC: 5424271. DOI: 10.14348/molcells.2017.2270. View

Finn R, Zhu A, Farah W, Almasri J, Zaiem F, Prokop L . Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis. Hepatology. 2017; 67(1):422-435. DOI: 10.1002/hep.29486. View

10.

Li Y, Tang Z, Ye S, Liu Y, Xue Q, Chen J . Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol. 2002; 7(5):630-6. PMC: 4695564. DOI: 10.3748/wjg.v7.i5.630. View

11.

Lin S, Gregory R . MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015; 15(6):321-33. PMC: 4859809. DOI: 10.1038/nrc3932. View

12.

Lin X, He C, Sun T, Duan X, Sun Y, Xiong S . hsa-miR-485-5p reverses epithelial to mesenchymal transition and promotes cisplatin-induced cell death by targeting PAK1 in oral tongue squamous cell carcinoma. Int J Mol Med. 2017; 40(1):83-89. PMC: 5466395. DOI: 10.3892/ijmm.2017.2992. View

13.

Jones M, Lim H, Shen Y, Pleasance E, Chng C, Reisle C . Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Ann Oncol. 2017; 28(12):3092-3097. DOI: 10.1093/annonc/mdx523. View

14.

Lee K, Lin F, Hsu T, Lin J, Guo J, Tsai C . MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1. Biochim Biophys Acta. 2014; 1843(9):2055-66. DOI: 10.1016/j.bbamcr.2014.06.001. View

15.

Saldanha A . Java Treeview--extensible visualization of microarray data. Bioinformatics. 2004; 20(17):3246-8. DOI: 10.1093/bioinformatics/bth349. View

16.

Karbownik M, Szemraj J, Wieteska L, Antczak A, Gorski P, Kowalczyk E . Antipsychotic Drugs Differentially Affect mRNA Expression of Genes Encoding the Neuregulin 1-Downstream ErbB4-PI3K Pathway. Pharmacology. 2016; 98(1-2):4-12. DOI: 10.1159/000444534. View

17.

Vignot S, Lefebvre C, Frampton G, Meurice G, Yelensky R, Palmer G . Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles. Eur J Cancer. 2015; 51(7):791-9. DOI: 10.1016/j.ejca.2015.02.012. View

18.

Liu F, Wu L, Wang A, Xu Y, Luo X, Liu X . MicroRNA-138 attenuates epithelial-to-mesenchymal transition by targeting SOX4 in clear cell renal cell carcinoma. Am J Transl Res. 2017; 9(8):3611-3622. PMC: 5575175. View

19.

Caswell D, Swanton C . The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med. 2017; 15(1):133. PMC: 5514532. DOI: 10.1186/s12916-017-0900-y. View

20.

Yoshida G . Emerging role of epithelial-mesenchymal transition in hepatic cancer. J Exp Clin Cancer Res. 2016; 35(1):141. PMC: 5020508. DOI: 10.1186/s13046-016-0419-7. View